World premiere in Wels: Paralympics star receives revolutionary prosthesis!

Veröffentlicht:

Von:

At the Wels-Grieskirchen Clinic in Austria, a medical milestone was celebrated: For the first time, a prosthesis on the collaborative artery was used worldwide. The patient who benefits from the innovative process is Egon Kramminger, a 76-year-old Paralympics participant. In a single operation, both a heart valve defect and an extended abdominal artery were remedied.

The classic entrances to carry out these interventions were not possible, which underlined the need for an innovative approach. An individually made prosthesis that was imported from Australia played a central role in this unique intervention. The success of this method is considered a medical novelty with a role model. Just two weeks after the operation, Krammingen was able to return home and even play his table tennis game again. This reports OE24

innovation in cardiac medicine

This groundbreaking technology is in a larger context of developments in the field of cardiac medicine. At the Hannover Medical School (MHH), work is also being carried out on innovative procedures to replace heart valves minimally invasively. So far, this type of treatment was only possible for three of the four heart valves. The latest progress now enables the tricus pidal flap to be treated with a new catheter system. This procedure was established as one of the first in Germany.

Professor Dr. Johann Bauersachs, a leading cardiologist of the MHH, emphasizes how important this innovation is for patients with severe leaks of the tricus pidal flap. This flap regulates the blood flow between the right atrium and the right handkan. Ventures can lead to health problems such as shortness of breath, water retention and fatigue. The first patient, Karin D., received the Evoque prosthesis in Lower Saxony at the end of March 2024. She suffered from leaving two heart valves and felt well two days after the implantation.

advantages of minimally invasive technology

The Evoque prosthesis is brought into the heart via a groin access and the hollow vein, where it is anchored in the natural heart valve. The process takes place under general anesthesia and is monitored by ultrasound. The patient can usually be released after a few days, and the symptoms often decrease quickly after the implantation, which significantly improves the quality of life. This advances show the potential of minimally invasive interventions and open up new opportunities in the treatment of heart valve diseases. The clinic hopes to be able to help many patients with the new system in the future. Further details on the treatment can be read on the website of Orf . The MHH also explains its innovative approaches in this area on its website, which you can find